NASDAQ:CDTX

Cidara Therapeutics - CDTX Stock Forecast, Price & News

$0.64

-0.01 (-1.55%)

(As of 10/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.63
▼
$0.65
50-Day Range: $0.55
▼
$0.81
52-Week Range: $0.40
▼
$1.90

Volume: 104,723 shs
Average Volume: 367,928 shs
Market Capitalization: $43.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Cidara Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 843.0% Upside
$6.00 Price Target
Short Interest: Healthy
0.86% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.92
Based on 2 Articles This Week
Insider Trading: Selling Shares
$35,625 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.69) to ($0.08) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

215th out of 1,072 stocks

Biological Products, Except Diagnostic Industry

29th out of 171 stocks

3.5

Analyst's Opinion

Consensus Rating
Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Cidara Therapeutics has a forecasted upside of 843.0% from its current price of $0.64.
Amount of Analyst Coverage
Cidara Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.86% of the outstanding shares of Cidara Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Cidara Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cidara Therapeutics has recently decreased by 0.82%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cidara Therapeutics does not currently pay a dividend.
Dividend Growth
Cidara Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Cidara Therapeutics is -0.85.

2.7

News and Social Media Coverage

News Sentiment
Cidara Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Cidara Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 17 people have searched for CDTX on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,625.00 in company stock.
Percentage Held by Insiders
Only 6.78% of the stock of Cidara Therapeutics is held by insiders.
Percentage Held by Institutions
Only 39.42% of the stock of Cidara Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cidara Therapeutics are expected to grow in the coming year, from ($0.69) to ($0.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cidara Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cidara Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cidara Therapeutics has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cidara Therapeutics (NASDAQ:CDTX) Stock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Stock News Headlines

October 4, 2022 | seekingalpha.com

Cidara spikes on $11M milestone payment from partner Mundipharma

October 4, 2022 | finance.yahoo.com

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

September 21, 2022 | finance.yahoo.com

Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review

September 21, 2022 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Cidara Therapeutics (CDTX)

September 20, 2022 | finance.yahoo.com

Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

September 13, 2022 | finance.yahoo.com

Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

September 7, 2022 | reuters.com

Cidara Therapeutics Inc

September 6, 2022 | finance.yahoo.com

Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

August 1, 2022 | msn.com

Short Volatility Alert: Cidara Therapeutics, Inc.

July 28, 2022 | nasdaq.com

Insiders who purchased Cidara Therapeutics, Inc. (NASDAQ:CDTX) stock last year recover some losses which currently stand at US$115k

July 28, 2022 | finance.yahoo.com

Even after rising 17% this past week, Cidara Therapeutics (NASDAQ:CDTX) shareholders are still down 89% over the past five years

July 27, 2022 | msn.com

Cidara Pursues FDA Approval For Bloodstream Infections Candidate

July 27, 2022 | nasdaq.com

Cidara Therapeutics Submits NDA For Rezafungin, Assigns U.S. Rights To Melinta In $460 Mln Deal

July 27, 2022 | finance.yahoo.com

With FDA Submission, Cidara Therapeutics Inks US Pact For Bloodstream Infection Candidate

July 27, 2022 | seekingalpha.com

Cidara stock soars 29% on FDA approval filing for rezafungin, sale of US rights for drug for $30M upfront

July 27, 2022 | finance.yahoo.com

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

June 10, 2022 | finance.yahoo.com

Insiders who purchased Cidara Therapeutics, Inc. (NASDAQ:CDTX) stock last year recover some losses which currently stand at US$137k

May 16, 2022 | nasdaq.com

Cidara Therapeutics vs. Bitcoin: Price Relationship Crosses Threshold

May 13, 2022 | finance.yahoo.com

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

May 12, 2022 | seekingalpha.com

H.C. Wainwright analyst lowers price target on Cidara Therapeutics

May 11, 2022 | benzinga.com

Recap: Cidara Therapeutics Q1 Earnings

May 11, 2022 | finance.yahoo.com

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

April 26, 2022 | finance.yahoo.com

Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

April 14, 2022 | finance.yahoo.com

Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022

April 1, 2022 | seekingalpha.com

Cidara gains on dosing milestone in early-stage trial for flu candidate

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Company Calendar

Last Earnings: 8/09/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CDTX
CUSIP: N/A
CIK: 1610618
Web: www.cidara.com
Phone: (858) 752-6170
Fax: N/A
Employees: 89
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +843.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,470,000.00
Net Margins: -239.94%
Pretax Margin: -239.94%
Return on Equity: -1,522.85%
Return on Assets: -119.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.16
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: $49.57 million
Price / Sales: 0.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.32 per share
Price / Book: 1.99

Miscellaneous

Outstanding Shares: 69,049,000
Free Float: 64,367,000
Market Cap: $43.94 million
Optionable: Optionable
Beta: 1.47

Key Executives

Dr. Jeffrey L. Stein Ph.D. (Age 67)
Pres, CEO & Exec. Director
Comp: $836.4k

Dr. Taylor Sandison (Age 50)
Chief Medical Officer
Comp: $597.9k

Dr. Les Tari Ph.D.
Chief Scientific Officer

Dr. Kevin M. Forrest Ph.D. (Age 45)
Founder and Chief Strategy Officer

Dr. Preetam Shah M.B.A. (Age 49)
Ph.D., CFO, Chief Bus. Officer & Principal Accounting Officer

Mr. Paul Daruwala (Age 53)
Chief Operating Officer

Mr. Shane M. Ward (Age 47)
Chief Legal Officer & Corp. Sec.

Ms. Allison Lewis CCP
SPHR, VP of HR

Mr. James M. Balkovec
Sr. VP of Research

Ms. Laura A. Navalta
Sr. VP of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDTX Stock - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings or view top-rated stocks.
What is Cidara Therapeutics' stock price forecast for 2022?: 4 Wall Street research analysts have issued 1 year price targets for Cidara Therapeutics' shares. Their CDTX share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 826.8% from the stock's current price.
View analysts price targets for CDTX or view top-rated stocks among Wall Street analysts.
How have CDTX shares performed in 2022?: Cidara Therapeutics' stock was trading at $1.27 at the beginning of 2022. Since then, CDTX stock has decreased by 49.0% and is now trading at $0.6474.
View the best growth stocks for 2022 here.
When is Cidara Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CDTX earnings forecast.
How were Cidara Therapeutics' earnings last quarter?: Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.09. The biotechnology company earned $6.22 million during the quarter, compared to analysts' expectations of $7.30 million. Cidara Therapeutics had a negative net margin of 239.94% and a negative trailing twelve-month return on equity of 1,522.85%.

What other stocks do shareholders of Cidara Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).
When did Cidara Therapeutics IPO?: (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.
What is Cidara Therapeutics' stock symbol?: Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."
How do I buy shares of Cidara Therapeutics?: Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cidara Therapeutics' stock price today?: One share of CDTX stock can currently be purchased for approximately $0.65.
How much money does Cidara Therapeutics make?: Cidara Therapeutics (NASDAQ:CDTX) has a market capitalization of $44.70 million and generates $49.57 million in revenue each year. The biotechnology company earns $-42,470,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.
How can I contact Cidara Therapeutics?: Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The official website for the company is www.cidara.com. The biotechnology company can be reached via phone at (858) 752-6170 or via email at britchie@lifesciadvisors.com.

This page (NASDAQ:CDTX) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cidara Therapeutics - CDTX Stock Forecast, Price & News

Cidara Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows